No Data
No Data
No Data
Yaojia Health, from Nanjing, Jiangsu, submitted an IPO prospectus and plans to list on the Hong Kong Stock Exchange. Citic and Huatai are joint sponsors.
On June 27, 2024, Jiangsu-based TransThera Sciences (Nanjing), Inc., also known as "药捷安康", submitted a prospectus to the Hong Kong Stock Exchange and plans to be listed on the main board of the exchange. This is their second attempt after their application was invalidated on August 25, 2021.
Hong Kong Stock IPO | Another unprofitable biopharmaceutical company, Pharmacie Ankang plans to go public in Hong Kong
On August 26, Capital State learned that Pharmaceutical Jieankang submitted a prospectus to the Hong Kong Stock Exchange to be listed on the Hong Kong Main Board. According to the prospectus, Pharmaceutical Jieankang is an R&D-oriented, clinical-stage global biopharmaceutical company focusing on the discovery and development of small-molecule innovative therapies for tumors, inflammation, and cardiovascular diseases. According to Frost & Sullivan, Pharmacojet Ankang is one of the first Chinese developers dedicated to innovating small molecules to establish a global R&D and clinical development platform. As of the last practical date, in key cancer treatment areas, Pharmaceutical Jieankang has five small tumor molecule products, including
New stock news | Pharma Jie Ankang is on the list of the Hong Kong Stock Exchange, focusing on small molecule innovative therapy.
Drug Jie Ankang submitted its listing application to the main board of the HKEx, with Jefferies, Huatai International and China Renaissance Capital Investment as co-sponsors, according to the Hong Kong Stock Exchange on Aug. 25.
New share news | Pharma Jie Ankang submitted an application with the China Securities Regulatory Commission to list Hong Kong H-share IPO.
Zhitong Financial APP learned that on August 13, the International Department of the China Securities Regulatory Commission disclosed the materials submitted by Pharmaceutical Jie Ankang (Nanjing) Science and Technology Co., Ltd. (referred to as "Pharmaceutical Jie Ankang") for the examination and approval of overseas initial public offering shares (including common shares, preferred shares and other stocks and stock derivative forms). Once accepted, it means that Jie Ankang may soon submit a prospectus on the Hong Kong Stock Exchange. It is reported that Pharmaceutical Jie Ankang, founded in 2014 and headquartered in Nanjing, Jiangsu Province, is an innovative small molecule new drug research and development company, mainly developing innovative drugs that do not meet clinical needs and have obvious differences. The company had previously
Yaojie Ankang completed about US $100 million in D-round financing, which was jointly led by CPE Yuanfeng and the Guomiao Fund.
Recently, Pharmaceutical Jie Ankang (Nanjing) Technology Co., Ltd. (referred to as "Pharmaceutical Jie Ankang") announced the completion of D-round financing of about 100 million US dollars. This round of financing is jointly led by CPE Yuanfeng and Guodian Fund, and followed by Sixty Degree Capital, China Merchants Capital, Jinpu Health Fund, Cornerstone Capital and Jiangsu Ruihua, including original shareholders. The funds raised in this round will be used to continue to promote the international development of the pipeline project. China Renaissance Capital Investment serves as the exclusive financial adviser for this round of financing. Ms. Wu Jing, Executive Director of CPE Yuanfeng, said, "Pharmaceutical Jie Ankang is a
No Data